Clenbuterol    (DrugBank: Clenbuterol)

4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
1球脊髄性筋萎縮症1
2筋萎縮性側索硬化症1
6パーキンソン病1
256筋型糖原病2

1. 球脊髄性筋萎縮症 [臨床試験数:17,薬物数:16(DrugBank:8),標的遺伝子数:10,標的パスウェイ数:15
Searched query = "Spinal and bulbar muscular atrophy", "Spinobulbar muscular atrophy", "SBMA", "Kennedy disease", "Kennedy-Alter-Sung syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 17 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022558-18-IT
(EUCTR)
11/10/201028/09/2012A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA).A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA). spinal and bulbar muscular atrophy (SBMA)
MedDRA version: 15.0;Level: HLGT;Classification code 10029317;Term: Neuromuscular disorders;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 15.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;Level: LLT;Classification code 10047868;Term: Weakness of limbs;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 15.0;Level: PT;Classification code 10013969;Term: Dyspnoea at rest;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: MONORES*30CPR 20MCG
INN or Proposed INN: Clenbuterol
AZIENDA OSPEDALIERA DI PADOVANULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
Italy

2. 筋萎縮性側索硬化症 [臨床試験数:508,薬物数:530(DrugBank:146),標的遺伝子数:170,標的パスウェイ数:221
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04245709
(ClinicalTrials.gov)
February 10, 202026/1/2020Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral SclerosisA Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: ClenbuterolDwight Koeberl, M.D., Ph.D.NULLActive, not recruiting18 YearsN/AAll25Phase 2United States

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-003796-17-GB
(EUCTR)
22/10/202001/09/2020A study to look at the effect of CST-103 or CST-139 on blood flow in the brain and on memory.An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139 Patients with Mild Cognitive Impairment or Parkinson’s Disease
MedDRA version: 21.1;Level: LLT;Classification code 10009846;Term: Cognitive impairment;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Spiropent
Product Name: Clenbuterol HCl
Product Code: CST-103
INN or Proposed INN: CLENBUTEROL HYDROCHLORIDE
Trade Name: Berachin
Product Name: Tulobuterol
Product Code: CST-139
INN or Proposed INN: Tolubuterol Hydrochloride
Other descriptive name: TULOBUTEROL HYDROCHLORIDE
CuraSen Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
32Phase 2United Kingdom

256. 筋型糖原病 [臨床試験数:161,薬物数:114(DrugBank:23),標的遺伝子数:26,標的パスウェイ数:106
Searched query = "Muscle glycogenosis", "Muscular glycogenosis", "Muscle glycogen storage disease", "Muscular glycogen storage disease", "Glycogen storage disease type 0", "GSD0", "Glycogen synthase deficiency", "Glycogen storage disease type II", "GSDII", "Pompe disease", "Alpha-1,4-glucosidase acid deficiency", "Glycogen storage disease type III", "GSDIII", "Cori disease", "Glycogen debranching enzyme deficiency", "Glycogen storage disease type IV", "GSDIV", "Andersen disease", "Glycogen-branching enzyme deficiency", "GBED", "Glycogen storage disease type V", "GSDV", "McArdle disease", "Muscle phosphorylase deficiency", "Muscular phosphorylase deficiency", "Glycogen storage disease type VII", "GSDVII", "Tarui disease", "Phosphofructokinase deficiency", "PFK deficiency", "Glycogen storage disease type IX", "GSDIX", "Phosphorylase kinase deficiency", "Phosphoglycerate kinase deficiency", "PGK deficiency", "Glycogen storage disease type X", "GSDX", "Phosphoglycerate mutase deficiency", "Glycogen storage diseass type XI", "GSDXI", "Kanno disease", "Lactate dehydrogenase deficiency", "Glycogen storage diseass type XII", "GSDXII", "Aldolase A deficiency", "Glycogen storage diseass type XIII", "GSDXIII", "Beta-enolase deficiency", "Glycogen storage diseass type XIV", "GSDXIV", "Phosphoglucomutase deficiency", "Glycogen storage diseass type XV", "GSDXV", "Glycogenin 1 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 161 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04094948
(ClinicalTrials.gov)
January 1, 202217/9/2019Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe DiseasePhase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease Stably Treated With Enzyme Replacement TherapyPompe Disease (Late-onset)Drug: Clenbuterol;Drug: PlacebosDuke UniversityNULLNot yet recruiting18 YearsN/AAll40Phase 2United States
2NCT01942590
(ClinicalTrials.gov)
September 201311/9/2013Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement TherapyA Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement TherapyPompe DiseaseDrug: Clenbuterol;Drug: PlaceboDwight Koeberl, M.D., Ph.D.NULLCompleted18 YearsN/AAll17Phase 1;Phase 2United States